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Abstract
Background: Obesity is associated with a risk of gastroesophageal reflux disease. The pharmacodynamic efficacy of
proton pump inhibitors has not been specifically evaluated in obese subjects. The aim of this study was to compare
the antisecretory response to a single oral dose of 20 mg rabeprazole, 20 mg omeprazole and placebo in obese
subjects.
Methods: Gastric pH was monitored for 24 hours on three separate occasions in eighteen H. pylori-negative,
asymptomatic obese subjects. Subjects were given omeprazole, rabeprazole or placebo in a randomized order and
in a double-blind fashion. The main analysis criterion was 24-h percent of time post dose with intragastric pH above
3; secondary criteria were percentage of time above pH 4, median pH, [H+] concentrations and nocturnal acid
breakthrough (NAB). Results were analyzed using linear mixed models and Wilks test comparing variances.
Results: 24-h median [IQ] percentages of time with gastric pH above 3 and 4 were higher with rabeprazole than
omeprazole (46 [37–55] vs. 30 [15–55] %, 9 [5-11] % for placebo) but the differences did not reach statistical
significance (p = 0.11 and 0.24, respectively). Median acid concentrations were significantly lower with rabeprazole
than with omeprazole and placebo (22 [14–53] vs. 54 [19–130] and 95 [73–170] mmoles/l, p < 0.01) for all periods.
The number of NAB was significantly lower with rabeprazole than with omeprazole (median 1 [1,2] vs. 2 [1-3],
p = 0.04). Variances of 24-h data (pH above 3 and 4, median pH, [H+] concentrations) were significantly lower with
rabeprazole than with omeprazole (p < 0.0001).
Conclusions: In asymptomatic obese subjects the gastric antisecretory response to a single dose of rabeprazole
and omeprazole was strong and not significantly different between drugs despite a significantly more
homogeneous response with rabeprazole.
Trial registration: ClinicalTrial.gov: NCT01136317
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Background
Symptoms suggestive of gastroesophageal reflux disease
(GERD) are reported by 10-20% of the population in
Western countries [1]. Although GERD is a multifactor-
ial disease, being overweight and obese are established
as increasing the risk of developing GERD and its com-
plications [2]. In overweight and obese subjects, direct
mechanical factors and proinflammatory signals derived
from the visceral adipose tissue may account for an
increased occurrence of reflux episodes [3].
Acid-suppressive therapy is the main therapeutic option
in GERD. However, in spite of the well-documented
association between obesity and GERD, the impact
of being overweight/obesity on the efficacy of acid-
suppressive therapies is still poorly documented. No
study has established whether high body mass index
(BMI) might affect the pharmacodynamic and pharmaco-
kinetic profile of PPIs [4]. In fact, several mechanisms
such as changes in the volume of distribution of the drugs,
reduction in tissue blood flow and changes in drug clear-
ance could change the pharmacokinetics of drugs in obese
patients [5-7]. PPIs as prodrugs are lipophilic compounds
and may therefore have a different bioavailability in
obese individuals compared to lean individuals due to
variations in distribution. In addition, as most PPIs
are mainly metabolized by the liver cytochrome P450
(CYP450) pathway [8], metabolism may be affected in
the setting of obesity with fatty liver disease. Recently,
some studies have reported a lower rate of healing of
esophagitis symptoms control in patients with a high
BMI treated with esomeprazole [9,10]. Likewise, Chen
et al. observed that twice-daily 40 mg pantoprazole
induced a better symptomatic control of reflux esophagitis
in overweight/obese patients than once-daily 40 mg
pantoprazole [11]. Conversely, another study using a
retrospective design did not find any clear differences in
mucosal healing rate between lean and overweight/obese
patients treated with omeprazole or rabeprazole [12].
All these studies were conducted in patients receiving a
chronic treatment on an everyday basis. In fact, a group of
patients is encouraged to use PPIs on an on-demand basis
adapted on the occurrence of their symptoms. Although
the interest of this procedure has been established [13-15]
no study has carefully determined the pharmacodynamic
consequences of a such on-demand intake in obese
patients. We only recently showed using a post-hoc
analysis that the pharmacodynamic effects of a single
dose of rabeprazole and pantoprazole were not ham-
pered by obesity [16]. Thus, it is not known whether
PPI doses should be adjusted according to body weight,
especially when administered in a single dose as an
on-demand treatment.
The aim of this study was to investigate prospectively
the pharmacodynamic effects of single doses of 20 mg
rabeprazole and 20 mg omeprazole in obese asymptom-
atic subjects by monitoring gastric pH for 24 hours.
Methods
Subjects
This single-center study was conducted at the Clinical
Investigation Center of the University Hospital of Nantes
(CIC INSERM-04). Eighteen 13C-urea breath test Helico-
bacter pylori-negative (Heli-Kit®, Mayoly Spindler, Chatou,
France) obese volunteers between age 18 and 55 years
were enrolled into this clinical trial.
All obese subjects had a BMI from 30 kg/m2 to 40 kg/m2
and had no clinically significant disease as determined
by medical history. Subjects with clinically relevant
diseases such as cardiac, renal or hepatic impairment,
and patients with digestive symptoms suggestive of
reflux disease or dyspepsia were not included. In addition,
subjects were not included if they had known hypersensi-
tivity to a PPI or a component of the drug, or had re-
ceived acid-suppressing medications or a medication
likely to interact with acid secretion in the previous
month. Patients with a history of abdominal surgery
were not included. During the study, reliable contraceptive
methods were requested for nonmenopausal women.
Patients with consumption of alcohol more than 30 g/d
or smoking more than 5 cigarettes per day were not
enrolled, nor were patients with ongoing treatment by
immunosuppressive therapy, antifungal or antiretroviral
drugs. At the baseline enrollment, all patients underwent
biological tests of liver function as well as coagulation
parameters and ultrasonography of the liver to screen
for any findings suggestive of nonalcoholic fatty liver
disease. Also at the time of enrollment, anthropometric
characteristics (weight, height, abdominal perimeter)
were taken.
Study design
This was a randomized, double-blind, placebo-controlled,
three-way crossover trial. Before breakfast, subjects
received one indistinguishable capsule of 20 mg rabe-
prazole or 20 mg omeprazole or placebo in a randomized
order on three separate occasions. The marketed forms
available in France, Pariet® (rabeprazole) and Mopral®
(omeprazole), and the placebo (lactose tablet - Rodael
laboratories - Bierne – France) were reconditioned in
capsules by the central pharmacy of the hospital. Drugs
were controlled and dispensed by the central pharmacy
according to the randomization code for each subject.
Drug administration was separated by a washout period
of between 7 and 14 days.
The trial (ClinicalTrials.gov identifier: NCT01136317)
was performed according to the Good Clinical Practice
guidelines and in accordance with the principles for
experimentation as defined in the Declaration of Helsinki.
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The study protocol received approval from the local
Ethical Committee (Comité de Protection des Personnes,
Pays de Loire N°2). All subjects received detailed written
information about the trial and signed a consent form.
Study procedure
The gastric pH monitoring procedure was performed
according to the previously published procedure [17].
Briefly, all subjects were instructed to fast from 10:00 pm
the night prior to their visit until their arrival at the center
at 7:00 am, on each pH-monitoring day. The glass pH
electrode with incorporated reference (Jubileum 1.8®,
Microbioprobe and Telemedicine, Marigliano, Italy) was
inserted and placed 10 cm below the esophagogastric
junction as determined by the pH step-up method [18,19].
The study drug was taken at 7:30 am. Twenty-four-
hour ambulatory pH monitoring was then conducted
from 8:00 am to 8.00 am on the following day while
remaining in the center for all the entire 24 hours of re-
cording. For the 3 occasions, subjects were given similar
daily meals at the same predetermined hours (breakfast
at 8:30 am, lunch at 1:00 pm and dinner at 7:00 pm),
with a global intake of 1960 kcal/24 h (P:19%, L:32%,
G:49%). Only still mineral water and tea were allowed
without restriction. Smoking was not allowed. Subjects
were required to remain in a recumbent position from
10:00 pm to 7:00 am.
Analysis was performed on the 24-h recording time,
the diurnal period from 8:00 am to 10:00 pm; and the
nocturnal period from 10:00 pm to 8:00 am. The pri-
mary efficacy criterion was the percentage of time with
intragastric pH > 3. The secondary criteria were the per-
centage of time with pH > 4, median intragastric pH,
acid concentration and the occurrence of nocturnal acid
breakthrough (NAB). Nocturnal acid breakthrough was
defined as the occurrence of intragastric pH < 4 for more
than 1 h from 10:00 pm to 08:00 am [20].
Statistics
The number of subjects to be included was calculated
using the results of Williams et al’s study [21]. Using
percentage of time with pH above 3 as the primary end-
point, an alpha risk of 5% and a beta risk of 20%, and
considering a variation rate of 67%, 18 subjects were
needed to observe a significant difference between both
treatment groups.
pH-metric parameters have been expressed using me-
dians and interquartile ranges, and percentiles if needed.
Due to the crossover design of the study, mixed linear
models adapted for repeated measures were used in
order to compare treatment for main and secondary
criteria. Treatment and period of treatment were con-
sidered as fixed effects. A lack of carryover effect as well
as interaction treatment period was verified. In the model
used both for main and secondary criteria, the patient
was considered as a random factor. In order to test for
difference in the variability of response, variances of
tested parameters observed in each treatment group were
compared using Wilks test [22]. The difference was con-
sidered as significant for a p value < 0.05. Analyses were
performed with SAS statistical software version 9.3 (SAS
Institute Inc., Cary, North Carolina).
Results
Eighteen Caucasian subjects (36.8 ± 9.3 years, range
22–54; 9 females) completed the study and were ana-
lyzed. Median weight was 101 kg (Q1-Q3: 88–111), me-
dian BMI was 33.1 kg/m2 (Q1-Q3: 31.2-36.2) and median
abdominal diameter was 107 cm (Q1-Q3: 107–114).
Gastric acidity
The percentages of time with intragastric pH > 3
and pH > 4 are indicated in Table 1 for 24-h (Figure 1),
diurnal and nocturnal periods. For percent time pH > 3
no carryover effect nor period effect was observed,
but there was a significant treatment effect. The 24-h
median percent time pH > 3 was higher with both PPIs
as compared with the period with placebo (p = 0.0002 and
p < 0.0001 for omeprazole and rabeprazole, respectively).
Twenty-four-hour percent of time pH > 3 was greater
with rabeprazole than with omeprazole but the differ-
ence did not reach statistical significance (p = 0.11).
Regarding diurnal and nocturnal periods, percentages of
time above pH 3 were significantly higher with both PPI
as compared with placebo. The diurnal percentage of time
above pH 3 was higher with rabeprazole than with omep-
razole but the difference was not significant (p = 0.08).
Regarding the percentages of time with gastric pH above
4, there was a significant treatment effect for all considered
periods. Although percentage of time with intragastric
pH > 4 was higher with rabeprazole at any period time
considered, the differences between rabeprazole and
omeprazole were not statistically significant (Table 1,
Figure 1). However, for any considered period, variances
for time above pH 3 and pH 4 were significantly lower for
rabeprazole than for omeprazole (Wilks test, p < 0.0001).
Median gastric pH and acid concentration
Twenty-four-hour individual values of median intra-
gastric pH are shown in Figure 2. Despite higher and
more homogeneous values during the rabeprazole
period as compared with the omeprazole period (Figures 1
and 2) the difference did not reach statistical significance
(p = 0.25). The same was true for the diurnal and noc-
turnal periods (p = 0.30 and p = 0.13, respectively). For
the 24-hour and diurnal periods, variances for median
pH were statistically lower for rabeprazole than for
omeprazole (p < 0.0001).
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As far as gastric acid concentrations are concerned,
there was also a significant treatment effect. The median
acid concentrations were significantly lower with rabe-
prazole than with omeprazole and placebo for the three
considered analysis periods (Table 1, Figure 1). For any
period, variances for acid concentrations were statistically
lower for rabeprazole than for omeprazole (p < 0.0001).
Nocturnal acid breakthrough (NAB)
The overall number of NAB (for the 18 subjects) was
lower during the rabeprazole period (n = 24) than dur-
ing the placebo period (n = 36) and omeprazole period
(n = 37). The median occurrence of NAB per patient
was low, 2 (range 1–3) both for the placebo and omep-
razole periods, and 1 (range 1–2) for the rabeprazole
Table 1 Percentages of time with gastric pH above 3 and 4, and gastric acid concentrations for the 24-hour, diurnal
and nocturnal periods following a single dose of placebo, 20 mg omeprazole (O) or 20 mg rabeprazole (R) in 18 obese
volunteers
Rabeprazole Omeprazole Placebo p R vs. O
% time above pH3
• 24-hour period 46.5 (37.3-54.9) 29.7 (15.2-55.5) 8.8 (4.8-10.8) 0.10
• Diurnal period 52.1 (36.4-67.8) 32.3 (14.9-64.0) 10.2 (6.2-15.1) 0.08
• Nocturnal period 38.2 (24.2-56.6) 29.5 (6.7-49.2) 4.1 (1.9-13.2) 0.25
% time above pH4
• 24-hour period 33.4 (27.2-44.3) 21.3 (10 .1-38.9) 5.3 (2.5-8.2) 0.24
• Diurnal period 37.9 (25.1-49.7) 20.1 (9.8-48.6) 4.6 (1.8-8.5) 0.21
• Nocturnal period 27.7 (14.0-49.3) 20.1 (3.3-37.4) 3.1 (0.2-10.6) 0.46
Acid concentration [H+] mmol/l
• 24-hour period 22 (14–53) 54 (19–130) 95 (73–170) 0.01
• Diurnal period 27 (9–57) 53 (10–81) 97 (64–150) 0.05
• Nocturnal period 29 (18–48) 57 (23–160) 115(76–180) 0.01
Values are medians and Interquartiles (Q1-Q3).
max observation 
75th percentile 
25th percentile 
median 
mean 
min observation 
A B 
C D 
Figure 1 Box plots of percentage of time spent above pH 3 (A), pH 4 (B), median gastric pH (C) and median gastric acid concentration
(D) in 18 obese volunteer subjects after a single oral dose (20 mg) of rabeprazole, omeprazole or placebo during 24-hour gastric
pH monitoring.
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period, with a statistically significant difference between
omeprazole and rabeprazole (p = 0.04) (Table 2).
The median duration of NAB was shorter with both
PPIs, but there was no statistical difference between
the rabeprazole and omeprazole periods (p = 0.11). The
nadir pH and the median pH of NAB were significantly
different between the two active treatment and placebo
groups (p = 0.002, p = 0.04, respectively), but there was
no statistically significant difference between both drugs
(Table 2). These results remained unchanged even when
considering NAB on the more selective period after mid-
night, i.e. between 0:00 a.m. and 8:00 a.m.
Tolerability
No serious adverse event was reported during the study.
Four patients reported minor sides events likely associated
with the transnasal catheter (maxillary pain, pharyngeal pain,
nasal pain, epistaxis). These complaints were spontaneously
resolved and the patients recovered without sequelae.
Discussion
The results of this study show that in obese subjects a
single dose of 20 mg rabeprazole and 20 mg omeprazole
induced a significant reduction of gastric acidity as com-
pared with placebo. Statistical analysis exhibited a signifi-
cant treatment effect for all the analyzed criteria (percent
time with intragastric pH > 3 and 4 and median pH). As
far as the main endpoint was considered (percent time
with intragastric pH > 3), there was no statistically sig-
nificant difference between both drugs. However, there
was a statistically significant decrease (approximately
50%) in the median gastric acid concentration after
administration of 20 mg rabeprazole vs. 20 mg omepra-
zole (Table 1, Figure 1). Of interest is also the efficiency
of rabeprazole in significantly reducing the occurrence
of NAB. Reduced NAB episodes have previously been
reported even when using low doses of rabeprazole
(10 mg) in comparison with a standard dose of omepra-
zole (20 mg) or pantoprazole (40 mg) [23].
Previous studies in healthy, nonobese, H.pylori-nega-
tive subjects using similar methodology to compare the
antisecretory effects of single doses of various PPIs doc-
umented similar findings of increased mean intragastric
pH, increased percentage of time with pH > 3 or > 4, and
decreased intragastric [H+] with rabeprazole compared
with omeprazole, lanzoprazole or pantoprazole [24,25].
Regarding omeprazole, and although the omeprazole
dose (i.e. 20 mg daily) is the approved daily dose in the
treatment of GERD, several pharmacodynamics studies
have shown that it is not equivalent to the approved
regimens of the other PPIs (namely lansoprazole, panto-
prazole and rabeprazole). In addition, the inter-individual
variability of the antisecretory action of the 20 mg dose of
omeprazole has been well described from its introduction
in our therapeutic armamentarium [26,27]. In our study,
the lack of demonstration of a statistically significant
difference between omeprazole and rabeprazole for the
main endpoint, i.e. 24-h percent time pH > 3, may be
due to a second espece risk. This difference may also
suggest that in obese patients the overall antisecretory
difference between PPIs is less than that observed in
nonobese subjects or patients.
The pharmacokinetics of drugs may be affected by
obesity due to alterations in drug distribution mediated
by reduced tissue blood flow [6]. In addition, drug clear-
ance may be affected in obese patients as a result of
changes in renal and hepatic physiology [4]. The present
study does not explain the causes of observed differences
between the effects of the two PPIs in obese subjects.
Previous evidence of impaired cytochrome P450 metab-
olism reported in obesity [28] may partially account for
the observed advantage of rabeprazole over omeprazole
due to increased metabolism of rabeprazole by nonenzy-
matic pathways and decreased dependency on CYP2C
[29]. In fact, the influence of obesity on CYP450 appears
to be isoenzyme specific, with a decrease of CYP3A4
activity and an increase of CYP2E1.
Figure 2 Twenty-four hour median pH individual values in 18
obese volunteer subjects after a single oral dose (20 mg) of
rabeprazole, omeprazole or placebo during 24-hour gastric
pH monitoring.
Table 2 Characteristics of nocturnal acid breakthrough
(NAB) monitored using intragastric pH monitoring
following a single dose (20 mg) of rabeprazole,
omeprazole and placebo in 18 obese volunteers. Values
are medians and interquartiles (Q1-Q3)
NAB Rabeprazole Omeprazole Placebo p (OvsR)
Number 1 (1–2) 2 (1–3) 2 (1–3) 0.04
Minimal pH 0.7 (0.6-0.9) 0.5 (0.3-0.8) 0.4 (0.3-0.6) 0.53
Median pH 1.4 (1.2-1.5) 1.3 (0.8-1.5) 0.9 (0.7-1.1) 0.47
Duration (h) 5.1 (3.4-6.2) 6.5 (4.6-8.9) 9.2 (7.9-9.9) 0.11
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As illustrated by the significantly lower variances for
time above pH3 and pH4 and median pH and acid con-
centrations, the decreased variability of antisecretory
response with single-dose rabeprazole in obese subjects
may represent an advantage when using PPI intermittently
on demand in response to insufficiently controlled symp-
toms of GERD before suggesting a continuous treatment.
Further studies in obese subjects are needed to determine
whether these pharmacodynamic differences between
rabeprazole and omeprazole persist when taking the
drug consistently on a daily basis, as has previously
been documented in nonobese subjects [21].
Our study has several strengths. It is one of the first
pharmacodynamic studies specifically conducted in obese
subjects. Obese asymptomatic subjects were well charac-
terized in order to exclude any hepatic abnormality, and
pharmacodynamic data were obtained in rigorous condi-
tions using continuous monitoring of gastric pH. Our
study also has some limitations including small sample
size and the lack of a nonobese control group. In fact, the
final word on the effect of obesity on PPI pharmacokinet-
ics and pharmacodynamics will be given by a study, inves-
tigating both activities of a given PPI before and after
weight reduction, whether obtained by medical or surgical
treatment.
Conclusions
In conclusion, this study shows that in obese healthy
volunteers the overall antisecretory effect after a single
dose of 20 mg rabeprazole and 20 mg omeprazole,
when taken on an on-demand basis, is strong but not
significantly different between both drugs. However, the
antisecretory response seems to be more homogeneous
after rabeprazole. Finally, our results suggest that, from a
pharmacodynamic point of view, dose augmentation in
obese subjects is not justified.
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